Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Decreased Frontal Lobe Gray Matter Perfusion in Cognitively Impaired Patients with Secondary-Progressive Multiple Sclerosis Detected by the Bookend Technique.
MS and NMO: Partners No More.
Interferon beta 1a-induced severe autoimmune hepatitis in patients with multiple sclerosis: report of two cases and review of the literature.
Slowing of brain atrophy and reductions in new multiple sclerosis lesions sustained at three years in patients treated with Genzyme's LemtradaTM
Multiple sclerosis symptom recrudescence at the end of the natalizumab dosing cycle.
Product Insert, Amiloride HCl Tablets
Direct angiotensin AT2-receptor stimulation attenuates T-cell and microglia activation and prevents demyelination in experimental autoimmune encephalomyelitis in mice.
Adherence to interferon β-1a therapy using an electronic self-injector in multiple sclerosis: a multicentre, single-arm, observational, phase IV study.
A single-arm, open-label study of alemtuzumab in treatment-refractory patients with multiple sclerosis.
Repeated treatment with high dose cyclophosphamide for severe autoimmune diseases.
Magnetization transfer imaging in multiple sclerosis treated with alemtuzumab.
Celgene to Acquire Receptos, Advancing Leadership in Immune-Inflammatory Diseases
Minocycline, a tetracycline derivative, is neuroprotective against excitotoxicity by inhibiting activation and proliferation of microglia.
MARGA: Multispectral Adaptive Region Growing Algorithm for brain extraction on axial MRI.
A Multidimensional Computerized Adaptive Short-Form Quality of Life Questionnaire Developed and Validated for Multiple Sclerosis: The MusiQoL-MCAT.
Cryptococcal meningitis in a multiple sclerosis patient taking natalizumab.
Neuroprotective effects of riluzole in neurotrauma models: a review.
Immunoadsorption therapy in patients with multiple sclerosis with steroid-refractory optical neuritis.
Guillain-Barré syndrome in Colombia: where do we stand now?
The initiation and prevention of multiple sclerosis.
Pharmacokinetics of dalfampridine extended release 7.5-mg tablets in healthy subjects and individuals with mild and moderate renal impairment: An open-label study.
Agreement between physician's recommendation and fitness-to-drive decision in multiple sclerosis.
Recurrence or rebound of clinical relapses after discontinuation of natalizumab therapy in highly active MS patients.
Severe haematological complications during treatment with natalizumab.
Using experimental autoimmune encephalomyelitis as a model to study the effect of prenatal stress on fetal programming.

Pages